Orchid Pharma's annual profit drops 57%, auditor flags US subsidiary issues
Full-year profit fell to ₹45.2 crore from ₹106.5 crore a year ago. The auditor gave a qualified opinion on consolidated accounts due to unaudited US subsidiaries.
— 6 earlier stories on Orchid Pharma Ltd. →What's new
- Orchid Pharma's FY26 standalone net profit fell 57.5% to ₹45.2 crore from ₹106.5 crore a year earlier.
- Consolidated net profit dropped 79.4% to ₹20.5 crore, indicating severe margin compression.
- Auditors issued a qualified opinion on consolidated results, citing unaudited financials from three US subsidiaries.
Why this matters
The profit decline is sharp, but the auditor's qualified opinion is the more serious issue. It means the consolidated numbers cannot be fully trusted because the US subsidiaries' finances are unverified. This is a recurring governance problem, not a one-off.
What we're watching
- Whether the US subsidiary audit issue gets resolved before the next filing.
- The impact of prior credit rating downgrades on future funding costs.
- The path back to profitability after the full-year EPS collapse.
The full read
Orchid Pharma's FY26 numbers tell a story of collapsing profitability. Standalone net profit fell 57.5% to ₹45.2 crore from ₹106.5 crore, and the consolidated picture is worse: profit there dropped 79.4% to ₹20.5 crore. Full-year standalone EPS crumbled to ₹8.91 from ₹20.99. The Q4 standalone profit of ₹30.6 crore offered a modest rebound, but it came with an exceptional item reversal of about ₹0.5 crore and was not enough to salvage the year. The deeper concern is the auditor's qualified opinion on the consolidated accounts. The issue is three US subsidiaries whose financials remain unaudited, a recurring governance gap. This is the same company that saw a credit rating downgrade. The operational headwinds are now joined by a trust deficit in the numbers themselves.
Questions answered
- How severe was the profit decline for the full year?
- Standalone net profit fell 57.5% to ₹45.2 crore from ₹106.5 crore. Consolidated net profit was hit harder, dropping 79.4% to ₹20.5 crore, signaling that the cost pressures were amplified at the group level.
- Why did the auditor give a qualified opinion?
- The auditors could not verify the financial statements of three US subsidiaries because they were unaudited. This is a recurring issue, meaning it has happened before, and it prevents a clean opinion on the consolidated accounts.
- How did the fourth quarter compare to the rest of the year?
- Q4 standalone net profit of ₹30.6 crore was an improvement from a loss-making Q3 and up slightly from ₹27.8 crore a year ago. The full-year decline, however, shows this quarter-end recovery was not enough to offset a poor first nine months.
- What is the earnings per share impact?
- Standalone EPS collapsed to ₹8.91 for FY26 from ₹20.99 in the prior year. This 57% drop in per-share earnings directly reflects the profit erosion.
Orchid Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ORCHPHARMA →- 25 May 2026 · 7:38 PM IST Orchid Pharma's annual profit drops 57%, auditor flags US subsidiary issues
- 3d ago Orchid lands Russian partner for Exblifep; $178M over 10 years
- 35d ago NCLT clears Orchid-Dhanuka merger. Integration starts now.
- 39d ago Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
- 45d ago Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion